60
Jiangsu Hengrui
600276.SS·SSELianyungang CNFounded 197028,000 employees
Large CappharmaPublicOncologyMetabolicImmunology
Platform: Innov Pharma
Market Cap
$30B
All Drugs
8
Clinical Trials
13
Failed / Terminated
2
FDA Approved
1
Stock Price & Catalysts (600276.SS)
Loading 600276.SS stock data...
Drug Pipeline (8 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Fixatapinarof | 600-8613 | Preclinical | 2 | PLK4 | EoENB | ||
| Polalucimab | 600-6629 | Phase 3 | 3 | MALT1 | CML | ||
| 600-6147 | 600-6147 | Preclinical | 2 | GIP-R | MGACC | ||
| 600-1765 | 600-1765 | Approved | 1 | B7-H3 | OCD | ||
| Tezesacituzumab | 600-3446 | NDA/BLA | 1 | IL-23 | CLLCeliac | ||
| 600-1653 | 600-1653 | NDA/BLA | 1 | GLP-1R | ASPBC | ||
| Semainavolisib | 600-1876 | Phase 2/3 | 1 | SGLT2 | Urothelial CaPSP | ||
| 600-2830 | 600-2830 | Preclinical | 2 | PI3Kα | Atopic DermPsA |
SEC Filings & Financial Documents
SEC filings are not available for SSE-listed companies.
Jiangsu Hengrui trades on SSE (CN). SEC EDGAR only covers US-listed issuers.
Insider Trading Activity
Insider trading data is not available for non-US exchanges.
Catalyst Events (11)